(1) The cabinet shall conduct an annual review of all medications, services, and forms of treatment for enrollees with a diagnosis of sickle cell disease that are eligible for coverage under the Kentucky medical assistance program. The purpose of the annual review shall be to determine if the available covered medications, services, and treatments are adequate to meet the need of enrollees with a diagnosis of sickle cell disease and if Department for Medicaid Services should seek to expand coverage to include additional medications, services, and treatments.
(2) When conducting the annual review required by this section, the cabinet shall solicit and consider input from the general public with specific emphasis on obtaining input from individuals or groups with knowledge and experience in the area of sickle cell disease treatment.
(3) (a) No later than January 15, 2023, and no later than January 15 each year thereafter, the cabinet shall submit a report to the Legislative Research Commission for distribution to the appropriate subject matter committees. The report required by this subsection shall detail the cabinet’s findings from the annual review required by this section and any recommendations based on those findings.
(b) The cabinet shall make the report required by paragraph (a) of this subsection available on its Web site in a manner that is accessible by the general public.
(4) This section may be cited as Emily’s Law.
Effective: July 14, 2022
History: Created 2022 Ky. Acts ch. 96, sec. 1, effective July 14, 2022.